Literature DB >> 36006507

Multidisciplinary and standardized management of patients with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Amr Abdulazim1, Carla Küppers2, Katharina A M Hackenberg2, Eva Neumaier-Probst3, Mohamad Mansour Alzghloul3, Jörg Krebs4, Manfred Thiel4, Hester Lingsma5, Gabriel J E Rinkel2, Christoph Groden3, Nima Etminan2.   

Abstract

BACKGROUND: The appropriate management of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH) remains uncertain. We aimed to evaluate the effect of implementing a standardized protocol for detection and management of DCI after aSAH on cerebral infarction and functional outcome.
METHODS: We studied two cohorts of aSAH patients, one before (pre-implementation cohort: January 2012 to August 2014) and one after (post-implementation cohort: January 2016 to July 2018) implementation of a multidisciplinary approach, with standardized neurological and radiological assessment and risk-based medical treatment of DCI. We assessed the presence of new hypodensities on CT within 6 weeks after aSAH and categorized cerebral infarction into overall and DCI-related infarctions (hypodensities not within 48 h after IA repair and not attributable to aneurysm occlusion or intraparenchymal hematoma). Functional outcome was assessed at 3 months using the extended Glasgow outcome scale (eGOS), dichotomized into unfavorable (eGOS: 1-5) and favorable (eGOS: 6-8). We calculated odds ratios (OR) with corresponding 95% confidence intervals (CI's), and adjusted for age, WFNS grade, Fisher score, and treatment modality (aOR).
RESULTS: In the post-implementation (n = 158) versus the pre-implementation (n = 143) cohort the rates for overall cerebral infarction were 29.1% vs 46.9% (aOR: 0.41 [0.24-0.69]), for DCI-related cerebral infarction 17.7% vs. 31.5% (aOR: 0.41 [0.23-0.76]), and for unfavorable functional outcome at 3 months 37.3% vs. 53.8% (aOR: 0.30 [0.17-0.54]). For patients with DCI, the rates for unfavorable functional outcomes at 3 months in the post-implementation versus the pre-implementation cohort were 42.3% vs. 77.8% (aOR: 0.1 [0.03-0.27]).
CONCLUSIONS: A multidisciplinary approach with more frequent and standardized neurological assessment, standardized CT and CT perfusion monitoring, as well as tailored application of induced hypertension and invasive rescue therapy strategies, is associated with a significant reduction of cerebral infarction and unfavorable functional outcome after aneurysmal aSAH.
© 2022. The Author(s).

Entities:  

Keywords:  Delayed cerebral ischemia; Intra-arterial treatment; Perfusion CT; Subarachnoid hemorrhage; Vasospasm

Year:  2022        PMID: 36006507     DOI: 10.1007/s00701-022-05347-y

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.816


  19 in total

1.  Complication rate of intraarterial treatment of severe cerebral vasospasm after subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon angioplasty: Worth the risk?

Authors:  Daniela Adami; Joachim Berkefeld; Johannes Platz; Jürgen Konczalla; Waltraud Pfeilschifter; Stefan Weidauer; Marlies Wagner
Journal:  J Neuroradiol       Date:  2018-05-04       Impact factor: 3.447

2.  Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage.

Authors:  Andrew P Carlson; Daniel Hänggi; George K Wong; Nima Etminan; Stephan A Mayer; François Aldrich; Michael N Diringer; Erich Schmutzhard; Herbert J Faleck; David Ng; Benjamin R Saville; Thomas Bleck; Robert Grubb; Michael Miller; Jose I Suarez; Howard M Proskin; R Loch Macdonald
Journal:  Stroke       Date:  2020-03-06       Impact factor: 7.914

Review 3.  CT perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

Authors:  Charlotte H P Cremers; Irene C van der Schaaf; Emerens Wensink; Jacoba P Greving; Gabriel J E Rinkel; Birgitta K Velthuis; Mervyn D I Vergouwen
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

4.  Induced Hypertension in Preventing Cerebral Infarction in Delayed Cerebral Ischemia After Subarachnoid Hemorrhage.

Authors:  N Marlou Haegens; Celine S Gathier; Janneke Horn; Bert A Coert; Dagmar Verbaan; Walter M van den Bergh
Journal:  Stroke       Date:  2018-11       Impact factor: 7.914

5.  Early perfusion computerized tomography imaging as a radiographic surrogate for delayed cerebral ischemia and functional outcome after subarachnoid hemorrhage.

Authors:  Nima Etminan; Kerim Beseoglu; Hi-Jae Heiroth; Bernd Turowski; Hans Jakob Steiger; Daniel Hänggi
Journal:  Stroke       Date:  2013-03-28       Impact factor: 7.914

6.  Induced Hypertension for Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Randomized Clinical Trial.

Authors:  Celine S Gathier; Walter M van den Bergh; Mathieu van der Jagt; Bon H Verweij; Jan Willem Dankbaar; Marcella C Müller; Annemarie W Oldenbeuving; Gabriel J E Rinkel; Arjen J C Slooter
Journal:  Stroke       Date:  2017-11-20       Impact factor: 7.914

7.  Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion.

Authors:  D Hänggi; B Turowski; K Beseoglu; M Yong; H J Steiger
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-27       Impact factor: 3.825

8.  CT perfusion during delayed cerebral ischemia after subarachnoid hemorrhage: distinction between reversible ischemia and ischemia progressing to infarction.

Authors:  Charlotte H P Cremers; Pieter C Vos; Irene C van der Schaaf; Birgitta K Velthuis; Mervyn D I Vergouwen; Gabriel J E Rinkel; Jan Willem Dankbaar
Journal:  Neuroradiology       Date:  2015-06-02       Impact factor: 2.804

Review 9.  Management of delayed cerebral ischemia after subarachnoid hemorrhage.

Authors:  Charles L Francoeur; Stephan A Mayer
Journal:  Crit Care       Date:  2016-10-14       Impact factor: 9.097

10.  The critical care management of poor-grade subarachnoid haemorrhage.

Authors:  Airton Leonardo de Oliveira Manoel; Alberto Goffi; Tom R Marotta; Tom A Schweizer; Simon Abrahamson; R Loch Macdonald
Journal:  Crit Care       Date:  2016-01-23       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.